武汉费斯德生物科技有限公司, NewEast Biosciences 中国办事处
武汉费斯德生物科技有限公司是美国NewEast Biosciences在中国的办事处。NewEast Biosciences 在十二年前率先研发俩种独特的抗体。这俩种抗体仅仅识别活性的GTP酶或者突变的Oncogene。 GTP酶涉及(1)响应细胞表面受体激活的信号转导,包括跨膜受体,例如介导味觉、嗅觉和视觉的那些,(2)核糖体的蛋白质生物合成,(3)调节细胞分化、增殖、分裂和运动,(4)蛋白质通过膜的易位,(5)细胞内囊泡的运输,以及囊泡介导的分泌和摄取,通过GTP酶控制囊泡外壳组装。Oncogene侧是诱发癌症的基因。
我公司将向你提供以下的独一无二的三种抗体或者试剂盒: (1) 仅识别 GTP酶的活性构型的产品, 它可以让你能够量化GTP酶在细胞中的活性和分布。(2) 识别突变 Oncogene蛋白, 但不认识相应野生型的抗体。 (3) 对 cAMP 和 cGMP 具有超亲和力(无需乙酰化)ELISA检测试剂盒。这些产品被将近一千篇同行评议的文章所引用。
¥30,000.00
货号: 11126 | ||
产品全名: 人 CGRPR-RAMP1 Full Length 蛋白 | ||
规格: 10/50/100 µg | ||
基因符号 CALCRL; CRLR; LMPHM8 | ||
目标蛋白: CGRPR | ||
UNIPROT ID: Q16602 | ||
描述: 人 CGRPR-RAMP1 full length protein-synthetic nanodisc | ||
背景: The CGRP receptor (CGRPR) is a member of family B G protein coupled receptors (GPCRs), is expressed throughout the trigeminal system, including neurons and endothelial cells. They usually function with accessory proteins such as receptor activity modifying proteins (RAMPs) and Na/H exchange regulatory factors (NHERFs). CGRPR is a heterodimer complex of the calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein 1 (RAMP1). Therapeutics for migraine treatment are mostly targeting CRLR-RAMP1 protein-protein interaction surfaces, thereby blocking CGRP activity. | ||
物种/宿主: HEK293 | ||
分子量: The human full length CGRPR protein has a MW of 53.0 kDa | ||
Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization. | ||
储存和运输: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. | ||
|